Positive Patient Stories™

Investor Overview

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$13.43
Change (%) Stock is Up 0.02 (0.15%)
Volume68,449
Data as of 09/27/16 4:00 p.m. ET

Latest News

09/01/16
Paratek Pharmaceuticals, Inc. To Present at Two Upcoming Investor Conferences
08/15/16
Paratek Initiates Phase 3 Study of Oral-only Omadacycline in ABSSSI
08/04/16
Paratek Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial and Operating Results
07/22/16
Paratek Pharmaceuticals to Report Second Quarter 2016 Financial Results on August 4, 2016
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.